1 Broadway # 14, Cambridge, MA 02142
Aug. 31, 2022 – SynDevRx, Inc., a clinical-stage biotechnology company leading the development of treatments for obesity-accelerated cancers, today announced the presentation of new scientific data on its lead compound evexomostat (SDX-7320) in a series of fibrosis models demonstrating potent anti-fibrosis data monotherapy and in combination with the standard of care therapy nintedanib. Evexomostat significantly […]
What You Need To Know About Your Metabolic Health and Breast Cancer Breast Cancer Conversations is a podcast that discusses all things breast cancer! We share stories of those who have been diagnosed. We interview medical professionals, doctors, radiologists, and oncologists. We speak with advocates and caregivers. We are your voice! If you have questions, […]
SynDevRx, Inc. today announced the opening of a first-of-its-kind Phase 1b/2 study for patients with triple-negative breast cancer and baseline insulin resistance, testing the novel drug evexomostat (SDX-7320) in combination with standard-of-care treatment Halaven (eribulin, Esai). Evexomostat is among the first anti-cancer therapeutics being developed specifically for cancer patients with baseline metabolic dysfunction (obesity, type […]
SynDevRx, Inc., a clinical-stage biotechnology company leading the development of treatments for obesity-accelerated cancers, today announced a research collaboration with Maine Medical Center Research Institute’s Michaela Reagan, PhD. The collaboration will study the role of MetAP2 in obesity-accelerated growth and metastatic potential of multiple myeloma – a form of cancer that develops in bone marrow. […]
Leptin may be a primary mediator of exercise-induced improvements in breast cancer recurrence.
The opportunity to draw upon genetic data from large-scale, international consortia allows for triangulation of evidence using distinct methodological approaches that make orthogonal underlying assumptions and suffer from distinct sources of bias. The findings of our study support a potential causal effect of genetically predicted T2DM and/or fasting insulin levels, rather than genetically predicted fasting […]
Jim Shanahan from SynDevRx explains why metabo-oncology treatment modalities could be the answer to a rise in metabolic disorders and cancers.
SynDevRx, Inc., a clinical-stage biopharmaceutical company specializing in metabo-oncology, has announced the formation of its Prostate Cancer Medical Advisory Board (PCMAB), comprised of key opinion leaders and industry experts in clinical oncology research and prostate cancer patient care. The board’s overarching goal is to inform the development of SynDevRx’s lead drug candidate, SDX-7320, to target […]
With a global epidemic of obesity and diabetes and their known relationship to cancer, researchers and oncologists are turning their attention to metabolic hormones as promising new targets for cancer treatment.